Health & Medicare · Guide

Leqembi and Kisunla in NJ: new Alzheimer's drugs and Medicare

Who qualifies for the new anti-amyloid Alzheimer's drugs, what Medicare's registry rule means for your parent, the ARIA risk and MRI schedule, list prices, and the questions to ask a New Jersey memory specialist.

An older woman in a straw hat tending her garden

Leqembi (lecanemab) and Kisunla (donanemab) are the two drugs the FDA has approved that go after the disease process in early Alzheimer's, not only the symptoms. Both are antibodies that clear amyloid, a sticky protein that builds up in the brain. They are meant for people with mild cognitive impairment or mild dementia due to Alzheimer's, and a test has to confirm amyloid first. Neither one cures the disease or brings back lost memory. In the main trials, decline on a standard rating scale was 27% slower with Leqembi and 29% slower with Kisunla than with a placebo over about 18 months.

Medicare Part B covers both drugs for people who qualify, as long as the prescribing doctor reports on the treatment to a registry approved by the Centers for Medicare & Medicaid Services (CMS). After the Part B deductible ($283 in 2026), your parent pays 20% of the Medicare-approved amount. The harder parts are a side effect called ARIA, the brain MRIs needed to watch for it, and finding a specialist team that offers the drugs. This guide is general information, not medical advice. Only your parent's doctors can say whether a drug fits.

What are Leqembi and Kisunla?

They are lab-made antibodies, given by infusion or injection, that bind to amyloid and help the body clear it. The FDA labels say treatment should start only in the mild cognitive impairment or mild dementia stage, the group studied in the trials.

The older Alzheimer's pills, such as donepezil, help manage some symptoms, according to the National Institute on Aging (NIA). People in the Leqembi trials could keep taking them.

LeqembiKisunla
MakerEisai, with BiogenEli Lilly
First approved20232024
How it is givenIV about 1 hour, or a shot at homeIV about 30 minutes
How oftenIV every 2 weeks, or a shot every weekEvery 4 weeks
After 18 monthsCan move to IV every 4 weeks or a smaller weekly shotDoctor may stop sooner, once a PET scan shows amyloid is very low
MRI checksBefore starting, then after 1, 2, 3 and 6 monthsBefore starting, then before infusions 2, 3, 4 and 7

Two recent changes matter. In July 2026 the FDA approved the Leqembi Iqlik autoinjector as a starting dose, so a person can begin treatment with weekly shots at home instead of infusions every two weeks. The label says a health care provider must guide at least the first two shots and then decide whether your parent or a caregiver can give them. And in July 2025, Kisunla's label switched to a slower dose build-up over the first three infusions because it led to less ARIA.

Kisunla has a planned stopping point. In its main trial, 47% of people had amyloid low enough to stop by week 52 and 69% by week 76.

Who can get these drugs?

A person qualifies only if a doctor diagnoses mild cognitive impairment or mild dementia due to Alzheimer's and a test confirms amyloid in the brain. People in moderate or later stages were not studied and are not candidates.

Amyloid can be confirmed in three ways. A PET scan shows it directly. A spinal tap measures it in spinal fluid. And in May 2025 the FDA cleared the first blood test for this, the Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio, for adults 55 and older with symptoms who are seen in a specialty setting. The FDA says it is not a stand-alone test. Results must be read alongside other clinical information.

The doctor will also bring up a gene test for ApoE4. Both labels say ApoE4 testing should be done before treatment, after a conversation about what the results mean. About 15% of people with Alzheimer's carry two copies of the gene, and they have a higher rate of ARIA, including serious ARIA. In the Leqembi trial, people with two copies did not show a benefit on the main rating scale, although some other measures favored the drug. A person can still be treated without the test, but then nobody knows whether they are in the higher-risk group.

Some people face extra risk. The Leqembi label urges caution for people who need blood thinners. In its trial, 2.5% of people taking Leqembi with an anticoagulant had a bleed in the brain, compared with none on placebo. MRI signs of earlier tiny bleeds also raise the risk of ARIA. Make sure the specialist has your parent's full medication list, including aspirin.

What is ARIA, and how risky is it?

ARIA stands for amyloid-related imaging abnormalities. It means swelling (ARIA-E) or small bleeds (ARIA-H) in the brain that show up on an MRI. It usually causes no symptoms and fades, but it can be serious and, rarely, fatal, which is why both drugs carry a boxed warning.

In the trialsLeqembiKisunla
Any ARIA on MRI21% (placebo 9%)29%*
ARIA with symptoms3%3% swelling with symptoms*
Brain bleed over 1 cm0.7% (placebo 0.1%)1%*

*Kisunla figures come from the label's study of the current, slower dosing schedule, through 12 months. Under the original dosing in its main trial, ARIA showed up in 36% of people, compared with 14% on placebo.

The labels list headache, confusion, vision changes, dizziness, nausea and trouble walking as possible ARIA symptoms. Seizures can happen.

Tell the ER about the drug

ARIA swelling can look like a stroke. The labels warn doctors to think about ARIA before giving a clot-busting drug. If your parent is on Leqembi or Kisunla and has sudden symptoms, call 911 and tell the ER team the drug's name right away. Keep the name, dose and the specialist's phone number on a card in your parent's wallet. For the warning signs of stroke, see our stroke signs guide.

Does Medicare cover Leqembi and Kisunla?

Yes, under Part B, for people with Medicare who meet the medical criteria and whose doctor takes part in a CMS-approved registry or study. Your parent pays 20% of the Medicare-approved amount after the Part B deductible.

The registry rule comes from CMS's national coverage decision for this group of drugs. In practice it falls on the doctor, not the family. Under the CMS National Patient Registry, the prescribing clinician or staff submit information when treatment starts and then every six months for up to 24 months. CMS also lists other approved studies, including the Alzheimer's Association's ALZ-NET registry. When you call a practice, ask plainly, "Do you submit to the CMS registry for these drugs?" If the answer is no, Medicare will not pay there.

Plan on other costs too. Medicare.gov notes that the scans and tests before and during treatment can add to the bill. CT, MRI and PET scans fall under Part B at 20% after the deductible, and a hospital outpatient department may charge a separate copayment. For amyloid PET, CMS ended its national one-scan-per-lifetime limit in October 2023 and left coverage to the regional Medicare contractors, so ask before the scan whether it will be covered.

Other coverage changes the math:

  • Medigap. A Medigap plan or other secondary insurance can pick up some or all of the 20% Part B share, depending on the plan. Our guide to Medigap plans in New Jersey explains which plans cover what.
  • Medicare Advantage. Call the plan for cost details. Ask about prior approval, which infusion sites and MRI centers are in network, and the copay for each.
  • The at-home shot. Eisai says Leqembi Iqlik counts toward the Part D yearly out-of-pocket cap, which is $2,100 in 2026 and $2,400 in 2027. Medicare.gov also says that if someone does not meet the Part B criteria, a Part D plan might cover the drug. Check your parent's drug plan list during open enrollment. Our Part D 2027 guide covers the cap.

For free plan help, call New Jersey SHIP at 1-800-792-8820.

What do Leqembi and Kisunla cost?

At list price, treatment runs roughly $20,000 to $40,000 a year depending on the drug and dose. What your parent actually pays depends on Medicare, supplemental coverage and help programs.

Drug and doseList price
Leqembi IV, every 2 weeks$28,270 a year for a 165 lb person
Leqembi Iqlik start, weekly$770 a week ($60,060 over 18 months)
Leqembi Iqlik upkeep, weekly$385 a week ($20,020 a year)
Kisunla, every 4 weeks$731.49 per vial; a full 1,400 mg dose uses 4 vials

Leqembi prices are Eisai's list prices as of July 2026. IV Leqembi is dosed by weight, so the yearly cost changes with your parent's weight. The Kisunla price is Lilly's list price per 350 mg vial, as of October 1, 2026, which works out to about $2,926 for each full-dose infusion. List prices leave out infusion fees, MRIs and other tests.

Both companies run support programs. Eisai's Leqembi Companion program (1-833-453-7362) helps with insurance questions, and Eisai has a patient assistance program for eligible uninsured patients. Lilly Support Services is at 1-800-545-5979, and the Lilly Cares Foundation (1-800-545-6962) helps qualified people get Lilly medicines at no cost. Eisai's copay card is not valid for people on Medicare. If your parent has trouble with drug plan costs, New Jersey's PAAD program may help those under its income limits.

How does a New Jersey family get started?

Start with a firm diagnosis and a referral to a memory specialist, usually a neurologist or a hospital memory center, that already gives these drugs. Your parent's primary care doctor can make the referral.

  1. Get the diagnosis pinned down. Treatment requires mild cognitive impairment or mild dementia due to Alzheimer's. Our guide to getting a dementia diagnosis in New Jersey walks through the tests.
  2. Ask for a memory specialist who offers anti-amyloid treatment. Not every neurologist does. The Alzheimer's Association 24/7 Helpline at 1-800-272-3900 and Alzheimer's New Jersey at 1-888-280-6055 can talk through options and local resources.
  3. Expect screening visits. These include an amyloid test, a baseline MRI, a talk about ApoE4 testing and a review of medicines.
  4. Map the logistics. Find out where the infusions or first shots happen, where the MRIs are done and how far that is from home.
  5. Check costs before the first dose. Call the Medicare plan or Medigap insurer, and ask the practice's billing office what your parent will owe for each infusion and scan.

Questions worth asking the specialist:

  • Do you submit to the CMS registry or another CMS-approved study?
  • Which drug would you suggest for my mom, and why?
  • Where are infusions given, and could she use the at-home shot instead?
  • Who do we call at night or on weekends if she has a headache or new confusion?
  • Are there clinical trials she could join instead or as well?

For trials, Alzheimer's New Jersey runs a Clinical Trial Connections program, and the NIA's ADEAR Center (1-800-438-4380) can help families find studies.

How do we decide whether it is worth it?

It is a personal call that weighs a modest slowing of decline against real risk, frequent visits and cost. Yes and no can both be reasonable.

IV Leqembi means a trip every two weeks for 18 months, plus at least five MRIs in the first six months, counting the baseline scan. Kisunla means a monthly trip, and it may stop sooner. The at-home Leqembi shot cuts travel but needs someone steady enough to give a weekly injection and spot an allergic reaction. If your parent no longer drives, line up rides early. Our guide to rides to medical appointments lists options by county.

Whatever you choose, the steps that matter for every diagnosis still apply. Get legal papers signed while your parent can take part (see estate planning basics), and lean on the support listed in our guide to life after a dementia diagnosis.

Common questions

Does Medicare pay for Leqembi or Kisunla for my mom?

Yes, if she has mild cognitive impairment or mild dementia due to Alzheimer's, a test confirms amyloid, and her doctor takes part in a CMS-approved registry or study. Part B pays the rest after she meets the deductible ($283 in 2026) and pays 20% of the Medicare-approved amount. MRIs and other tests are billed separately.

What is the Medicare registry for Alzheimer's drugs?

It is a data collection program that CMS requires for coverage. The prescribing clinician or staff submit information when treatment starts and every six months for up to 24 months. Families do not fill anything out, but the doctor must participate, so ask before you book.

Can Leqembi be given at home?

Yes. In July 2026 the FDA approved Leqembi Iqlik, a weekly autoinjector, as a starting dose. A health care provider must guide at least the first two shots, then decides whether the patient or a caregiver can give them at home. MRI checks are still required.

How do I know if my dad is a candidate for the new Alzheimer's drugs?

He needs a diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's and a confirmed amyloid test, such as a PET scan, spinal fluid test or an FDA-cleared blood test. A memory specialist also weighs his MRI, his medicines (especially blood thinners) and ApoE4 status. Ask his primary care doctor for a referral.

What are the warning signs of ARIA?

The labels list headache, confusion, vision changes, dizziness, nausea and trouble walking. Seizures can occur. Most ARIA causes no symptoms and is found on scheduled MRIs. Call the specialist about any new symptom, and call 911 for sudden stroke-like symptoms, telling the ER which drug your parent takes.

Do Leqembi and Kisunla cure Alzheimer's?

No. They clear amyloid and, in trials, slowed decline on a rating scale by 27% (Leqembi) and 29% (Kisunla) compared with placebo over about 18 months. They do not stop the disease or restore memory.

This guide is for general information. Program rules and income limits change, so confirm with the official source before you apply.

An older man talking with his doctor at her desk
Health & Medicare

Free memory screening in NJ: where to go and what comes next

Where older adults in New Jersey can get a free memory screening, what Medicare covers, what a screening can and cannot tell you, what happens after a worrying result and how to bring it up with a parent.

8 min readGuide
An older woman smiling at her phone
Health & Medicare

Hearing loss and dementia risk: what NJ families should know

What the 2024 Lancet Commission and the ACHIEVE trial actually found about hearing loss and dementia, what Medicare covers, and how New Jersey helps pay for hearing aids.

7 min readGuide
An older man talking with his doctor at her desk
Health & Medicare

Getting a dementia diagnosis in New Jersey: the steps

How a dementia evaluation works, from the first doctor visit to brain scans and specialists, what Original Medicare pays for each test, the closest research centers to New Jersey, and how to prepare your mom or dad.

8 min readGuide
A pharmacist explaining a prescription to an older woman
Health & Medicare

Managing many medications: help for older adults in NJ

A pharmacist review through the Medicare drug plan, a list that works, the right pill box, and where to drop old medicines in New Jersey.

7 min readGuide
A grandmother hugging her granddaughter
Caregiving

After a dementia diagnosis: where New Jersey families can turn

Helplines, memory cafes, adult day and respite programs, safety steps and the legal planning to do now, for New Jersey families facing Alzheimer's or another dementia.

7 min readGuide
Two people holding hands
Caregiving

Thanksgiving and the holidays with a parent who has dementia

Smaller gatherings, earlier meals and a quiet room can make the season gentler for everyone. Practical, kind advice for families, plus New Jersey help for the caregiver.

8 min readGuide